Novartis moved to strengthen its neuroscience pipeline by paying Sironax $125 million for a blood-brain barrier crossing platform. The acquisition is designed to improve delivery of large therapeutic modalities into the CNS and is intended to support multiple programs, including continued development for aging- and neurodegeneration-related indications. The Sironax platform transaction comes as Novartis navigates R&D setbacks and seeks new technical pathways to overcome one of the most persistent constraints in CNS drug development: getting molecules to reach relevant brain targets. For CNS-focused biotech strategy, the deal underscores how modality-agnostic delivery platforms can act as a lever for broad pipeline expansion rather than a single-asset bet.